Regulated
Can sell early
- Risk level
- Highest
- Risk-return
- Medium
- Start from
- €500
Funding closed on 15 Sep 2026. The page stays up for reference; similar open projects are below.
Aspivix
Switzerland
Aspivix is modernizing gynecology with carevix®, the only clinically proven, non-traumatic alternative to the cervical tenaculum used during intrauterine device (IUD) procedures.
Key figures
- Estimated return
- 4–7×
- platform's estimate
- Valuation
- €26,318,642
- Stake offered
- 2.48
- Exit expected
- 2029
- Funding ends
- 15 Sep 2026
- Start from
- €800
- Target
- €675,545
What you own, how it can pay off, and when
What do I own?
2.48 of the company
Check the documents for how the shares are held and what rights they give.
How can it pay off?
The platform estimates 4–7×
Usually only if the company is sold or listed. Estimates are the platform's own claims.
When could I get money?
Around 2029
Only if a sale or listing happens; shares are hard to sell before that.
Capital at risk. Most startups fail; estimates are the platform's own claims. Shares are hard to sell before an exit.
Would AI invest?
AI 73 HighOur AI gives this project 73 out of 100: High. How the AI score works
Information, not personal investment advice. The AI score rates the documents the platform publishes, can be wrong, and does not predict returns.
AI review
AIAspivix SA — Crowdfunding Investor Memo
A medical-device company selling a gentle, suction-based tool (carevix®) that doctors use to hold the cervix steady during coil (IUD) fittings and similar procedures — replacing a sharp clamp that often causes pain.
Sector: Medical devices (women’s health) · Stage: Series B2, first closing · HQ: Epalinges, Switzerland · Raise: €675,545 target (max €3,999,998)
Snapshot
|
1 · Is the price fair? 💶 |
2 / 5 — stretched. The €26.3M asking value is about 80 times last year’s revenue, while the similar businesses the company lists were sold at about 6.9 times revenue. Not supported by the exit benchmarks we could find. |
|
2 · Can they reach an exit stage? ⭐ |
AI SCORE 73 / 100 — Good — the building blocks for reaching a sale are largely in place (approved in five markets, real sales, named buyers with a track record of similar purchases); the main gap is that sales are still small and cash runway was not in the pack. |
|
3 · If they do, what could it pay? 🎯 |
Target 4x–7x over ~2–3+ years (the company’s own plan). If reached, that implies a sale of roughly €105M–€185M — within the range of past sales recorded in this sector ($44M to $1.6B). Illustrative only, before fees and future dilution. |
How to read the score
|
85–100 · Excellent |
All key building blocks for reaching a sale are evidenced and strong — rare at this stage. |
|
70–84 · Good |
Building blocks largely in place, with specific gaps — named in the questions section. |
|
50–69 · Average |
Meaningful building blocks missing or only weakly evidenced. |
|
30–49 · Weak |
Several core building blocks absent, or the evidence points against them. |
|
1–29 · Critical |
Fundamental building blocks are not visible in the evidence. |
|
What we could check. We verified the medical approvals in five countries, the TIME 2024 award, the Bayer collaboration and the company’s earlier funding rounds against public sources — all hold up. The revenue, profit-margin and ownership figures come from the company’s own materials and could not be checked independently, and the exact rules for splitting proceeds if the company is sold were not in the pack we reviewed. See the questions section before investing. |
|
Three answers, one honest note. The fairness score says whether the entry price is supported by the sector benchmarks we could find. The AI Score is our read on whether the company has the building blocks in place to reach a stage where a sale or other return event can happen — it checks readiness on the disclosed evidence; it is not a probability of success, and even companies with every building block in place fail more often than they succeed, which is why crowdfunding only works as a small part of a spread-out portfolio. The potential returns range is an illustration of what a successful sale could pay, drawn from named past sales in this sector — not a forecast. Where something was not in the pack, it did not lower any score — it appears in the questions list instead, so you can ask the company directly. The listing was reviewed by a licensed crowdfunding platform (Capital Cell) before going live. Nothing here is a recommendation.
At a glance
|
✅ Three reasons to look closer |
⚠️ Three reasons for caution |
|
|
|
Deal terms. No terms were identified in the reviewed documents that would prevent a crowdfunding investor from sharing in the upside. Note that the exact rules for splitting proceeds if the company is sold — how much is paid out first, and how the rest is divided — were not in the pack we reviewed, so this all-clear rests on what was disclosed. Those items are in the questions section. Full mechanics are at the end of this memo. |
|
ℹ️ Information, not investment advice. Capital at risk — you could lose the full amount invested. Full notes are at the end of this memo. |
🏢 What the company does
Aspivix is a Swiss company that makes a single-use medical device called carevix®. During common gynaecological procedures — most often fitting a coil (an IUD, a long-lasting contraceptive) — a doctor needs to hold the cervix steady. The standard tool for this is a sharp, clamp-like instrument (a tenaculum) that often causes pain and bleeding, and the company reports that fear of that pain stops more than 30% of women from choosing a coil at all. carevix grips using gentle suction instead. Its customers are clinics and hospitals, and because the device is thrown away after each use, buyers reorder it — the company reports a 21% repeat-order rate in Switzerland and a profit margin of 88% on US sales. The company reports it is selling in the US and 13 other countries, reached about 10% of the Swiss market, and earned about USD 330k in 2025 with a target of about USD 1.5M in 2026. Third-party databases record the company as founded in 2015 by Julien Finci and Mathieu Horras, while the platform document gives a 2018 registration and names only CEO Mathieu Horras. This round is the first part of a larger “Series B2” fundraising and is intended to pay for sales expansion in Europe and the US and to develop a next-generation device, carevix evo.
📈 The…
The full review covers the borrower or company, the security, the cash flow, the risks and a verdict. Sign in to read it.
Information, not personal investment advice. The AI score rates the documents the platform publishes, can be wrong, and does not predict returns.
Ask AI about this project
Sign in to ask the AI about this project's documents.
Sign inLike this project?
👍 Yes · 0 👎 No · 0
Comments · 0
- No comments yet.
The platform and similar projects
Offered on
Similar open projects
Kepplair Evolution
Sowefund
- Estimated return
- up to 7×
- platform's estimate
- Valuation
- €60,000,000
Raising €9m
From €500
See project
Wind Fisher
Sowefund
- Estimated return
- up to 10×
- platform's estimate
- Valuation
- €9,961,800
Raising €600k
From €1,000
See project
Blumana
Sowefund
- Estimated return
- up to 28×
- platform's estimate
- Valuation
- €2,799,571
Raising €750k
From €1,000
See project